Clinical Trials Logo

Hemangioma clinical trials

View clinical trials related to Hemangioma.

Filter by:

NCT ID: NCT03674346 Not yet recruiting - Angioma Clinical Trials

Efficacy of Hypnoanalgesia by a Radiologist Technologist in Children With Cutaneous Angioma Treated With Sclerosis in Interventional Radiology

HYP-ANGE
Start date: January 2024
Phase: N/A
Study type: Interventional

This study highlights the global management of the various components of outpatient pain by hypnoanalgesia (pain management by hypnosis) in radiopediatrics. Indeed, pain is induced by sclerosis of cutaneous angiomas in interventional radiology. It is managed by MEOPA (an equimolar mixture of oxygen nitrous oxide) or by general anesthesia. For four years, the medical electroradiology technologist of the Mother and Child Hospital (HFME) of the Hospices Civils de Lyon offer patients in addition a pain management by hypnoanalgesia. The investigator propose a multicenter open randomized study comparing two pain management strategies, in children aged 7 to 18 years treated for cutaneous angioma by sclerosis in interventional radiology at the HFME. The two strategies studied are: Hypnoanalgesia and MEOPA (the reference strategy). The main objective is to evaluate the efficacy of hypnoanalgesia compared to the standard of care of pain, which is the use of MEOPA, in the treatment of sclerosis of cutaneous angioma in pediatric interventional radiology.

NCT ID: NCT03656211 Completed - Clinical trials for Arteriovenous Malformations

Fertility After Diagnosis and Management of Acquired Uterine Arteriovenous Malformation

MAVUFERT
Start date: October 2, 2017
Phase:
Study type: Observational

Uterine arteriovenous malformations (UAVM) are short circuits between systemic arterial and venous networks within the uterus. They are congenital or acquired (in the course of an endo-uterine gesture such as curettage or interventions such as caesareans or myomectomies). They can be manifested by severe metrorrhagia that can go as far as to put the patient's vital prognosis at risk. There are no recommendations for the management of UAVM since this pathology is rare and therefore series are performed with few cases. If some of these UAVM disappear spontaneously after a therapeutic abstention, when the clinical context allows it, in case of symptomatic UAVM, a selective embolization with arteriography is often carried out to postpone the hysterectomy of hemostasis. There are also more marginal management options such as Gonadotropin-Releasing Hormone agonists, methotrexate or curettage that are decided on a case by case basis depending on the symptoms and protocols of each medical team. Regarding subsequent fertility and pregnancy outcomes after conservative treatment, the number of studies is even lower.

NCT ID: NCT03652181 Completed - Clinical trials for Cerebral Cavernous Malformation

CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness

Start date: August 20, 2018
Phase:
Study type: Observational

Brain Cavernous Angiomas with Symptomatic Hemorrhage (CASH) are rare, but they exact a heavy burden of neurologic disability from recurrent bleeding, for which there is no proven therapy. This trial readiness project aims to address current critical obstacles in identifying cases at multiple sites, characterizing their relevant features, and measuring their outcome. The timing cannot be more opportune, with therapeutic targets already identified, exceptional collaboration among researchers and with the patient community, and several drugs ready to benefit from a track to clinical testing in the next five years.

NCT ID: NCT03649113 Completed - Hemangioma Liver Clinical Trials

Percutaneous Sclerotherapy of Symptomatic Liver Hemangioma With Bleomycin

Hemangioma
Start date: September 1, 2018
Phase: Phase 1
Study type: Interventional

Percutaneous sclerotherapy is currently a widely used treatment for subcutaneous low-flow vascular malformations. Considered as a low-flow vascular malformation, symptomatic liver hemangiomas could also theoretically be safely and effectively treated by percutaneous sclerotherapy with a mixture of Bleomycin and Lipiodol. The safety and efficacy of percutaneous sclerotherapy was firstly introduced by the investigator's investigators in 5 patients in a pilot study. The aim of this study is to design and conduct a study to evaluate the safety and efficacy of percutaneous sclerotherapy in a larger sample size with a long term follow-up.

NCT ID: NCT03633747 Recruiting - Hemangioma Liver Clinical Trials

Efficacy Evaluation of Propranolol Treatment of Hepatic Hemangioma

Start date: July 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Hepatic hemangioma is one of the most common benign tumor of the liver. Although the overall prognosis is good, active interventions are still needed in high-risk patients. Without specific drugs, the main treatment methods include surgical treatments, interventional therapies and radiotherapies. Effective medical treatments are needed urgently. Propranolol has achieved good results in infantile Facial/hepatic hemangioma, and shows some effectiveness in adult hemangioma. Here, investigators intend to evaluate the therapeutic effect of propranolol in adult hepatic hemangioma.

NCT ID: NCT03571282 Recruiting - Clinical trials for Circumscribed Choroidal Haemangioma

Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma

Start date: June 6, 2018
Phase: Early Phase 1
Study type: Interventional

This prospective clinical trial aims to evaluate the safety and effectiveness study of intravitreal conbercept injection for exudative circumscribed choroidal haemangioma.

NCT ID: NCT03559556 Active, not recruiting - Clinical trials for Arteriovenous Malformations

Treating Arteriovenous Malformation With Stereotactic Radiosurgery Using CT Angiography for Treatment Planning

Start date: July 25, 2019
Phase: Early Phase 1
Study type: Interventional

Evaluate whether a treatment plan based on CT angiography can accurately and precisely identify the target nidus as compared to standard cerebral arteriography fused to MRI.

NCT ID: NCT03516162 Recruiting - Brain Tumor Clinical Trials

Linking Digital Smartphone Behaviour With Brain Function

SmartSurgery
Start date: April 20, 2018
Phase:
Study type: Observational

This study will thus examine daily behaviour based on smartphone use and link it to the neurological and neuropsychological status as well as to neuroradiological studies that are part of the clinical routine. The study will examine behaviour changes before and after surgery, and how this change in measured behaviour with the smartphone relates to today's "gold standard", namely professional neuropsychological examination and quantification of brain damage on imaging studies (MRI). This study is a proof-of-principle study that intends to build the basis for larger future observational studies on patients with focal or diffuse brain pathologies.

NCT ID: NCT03413852 Active, not recruiting - Clinical trials for Cerebral Arteriovenous Malformation

Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE)

CHOICE
Start date: May 11, 2018
Phase:
Study type: Observational [Patient Registry]

The objective of this study is to further establish that SQUID, an alternative liquid embolic agent with specific properties, is a safe and effective alternative in bAVM endovascular treatment strategy available to date. Therefore, the performance of SQUID will be documented and its safety of use will be confirmed in current practice.

NCT ID: NCT03367975 Recruiting - Clinical trials for Subarachnoid Hemorrhage

NIRS Monitoring During Intracranial Interventions

NIRS_ICG
Start date: March 2014
Phase: N/A
Study type: Observational

Near infrared spectroscopy is a valuable tool to monitor cerebral oxygenation during intracranial interventions. However, it yields artificial results when the dye indocyanine green (ICG) is applied, which is routinely done for intraoperative angiography. The investigators examine, to what extent and which duration NIRS is disturbed following ICG application.